Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas P D
INSERM U234, Pavillon F, Lyon, France.
Cancer Res. 1993 Mar 15;53(6):1421-30.
We have previously shown that thrombospondin (TSP) is present in normal breast secretions, and high levels of TSP are observed in malignant breast secretions and cytosols. Three genes encoding for three distinct TSPs (TSP1, TSP2, TSP3) have recently been described. In this study, using both immunohistochemistry and in situ hybridization, we report on the distribution of TSP1 in normal, hyperplastic, and neoplastic human breast. Its immunolocalization was also compared with that of two known cell surface receptors for TSP1: CD36 and CD51. In nonlactating ducts of normal and hyperplastic breast, TSP1 and CD51 are expressed in the basement membrane and in the basal surface of myoepithelial cells, respectively. In lactating adenomas, both TSP1 and CD51 disappear from the myoepithelial-stromal junction of ducts. However, TSP1 becomes selectively expressed at the apices of secretory epithelial cells of lactating ducts together with CD36, suggesting that the distribution of TSP1 and the appearance of its receptors are dependent on the secretory activity of human mammary ducts. In neoplastic human breast, a strong immunostaining for TSP1 is observed in the basement membrane surrounding in situ carcinomas (preinvasive cancer), and excessive TSP1 deposits are also observed in desmoplasia of invasive ductal carcinomas. TSP1 mRNA is localized in myoepithelial cells surrounding in situ carcinomas and in fibroblasts present in desmoplastic areas. On the other hand, few invasive ductal carcinoma cells (10%) express TSP1, while CD51 is moderately expressed by some neoplastic clusters, and no immunoreactivity is observed for CD36. By contrast, TSP1 is codistributed with CD51 in most of the invasive lobular carcinoma cells (40 to 80%) and with CD36 in a subpopulation (30 to 40%) of these invasive tumor cells. As previously observed with lactating adenomas, it is likely that the coexpression of TSP1 and CD36 is related to the secretory activity of invasive lobular carcinoma cells. The different distribution of TSP1 in invasive ductal versus lobular carcinomas may well reflect biological differences between these two main types of breast carcinoma. In this regard, the coexpression of TSP1 and CD36 may, in part at least, account for the variably invasive behavior of lobular carcinoma cells.
我们之前已经表明,血小板反应蛋白(TSP)存在于正常乳腺分泌物中,并且在恶性乳腺分泌物和胞质溶胶中观察到高水平的TSP。最近已经描述了编码三种不同TSP(TSP1、TSP2、TSP3)的三个基因。在本研究中,我们使用免疫组织化学和原位杂交技术,报告了TSP1在正常、增生性和肿瘤性人类乳腺中的分布情况。还将其免疫定位与两种已知的TSP1细胞表面受体CD36和CD51的免疫定位进行了比较。在正常和增生性乳腺的非泌乳导管中,TSP1和CD51分别在基底膜和肌上皮细胞的基表面表达。在泌乳性腺瘤中,TSP1和CD51都从导管的肌上皮 - 基质交界处消失。然而,TSP1与CD36一起在泌乳导管分泌上皮细胞的顶端选择性表达,这表明TSP1的分布及其受体的出现取决于人类乳腺导管的分泌活性。在肿瘤性人类乳腺中,在原位癌(侵袭前癌)周围的基底膜中观察到TSP1的强免疫染色,并且在浸润性导管癌促纤维增生中也观察到过量的TSP1沉积。TSP1 mRNA定位于原位癌周围的肌上皮细胞和促纤维增生区域中的成纤维细胞中。另一方面,很少有浸润性导管癌细胞(10%)表达TSP1,而一些肿瘤细胞簇中度表达CD51,并且未观察到CD36的免疫反应性。相比之下,在大多数浸润性小叶癌细胞(40%至80%)中TSP1与CD51共分布,在这些浸润性肿瘤细胞的一个亚群(30%至40%)中与CD36共分布。如之前在泌乳性腺瘤中观察到的那样,TSP1和CD36的共表达可能与浸润性小叶癌细胞的分泌活性有关。TSP1在浸润性导管癌与小叶癌中的不同分布很可能反映了这两种主要类型乳腺癌之间的生物学差异。在这方面,TSP1和CD36的共表达可能至少部分解释了小叶癌细胞的不同浸润行为。